New asthma drug shows promise in small trial
NCT ID NCT05280418
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested tezepelumab, a monoclonal antibody, in 27 adults with uncontrolled moderate-to-severe asthma. The goal was to see if it improves lung function and reduces airway inflammation and blockages. Participants received either tezepelumab or a placebo, and researchers used advanced imaging to measure changes over 16 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- tezepelumab (a monoclonal antibody)
- What this could lead to
- If successful, this could lead to a new treatment option that improves lung function and reduces airway blockages in people with uncontrolled asthma.
- What could go wrong
- This is a small, early-stage study with only 27 participants, so results may not apply to everyone. The drug may not show significant benefits over placebo.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ASTHMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Firestone Institute for Respiratory Health
Hamilton, Ontario, L8N 4A6, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can tracking severe asthma over time unlock better treatments?
- Can pressurized breathing boost mucus clearance in lung disease?
- Can a simple breathing test unlock the secrets of chronic cough?
- Can a Breath-Activated inhaler match the standard for asthma control?
- Can a School-Home program tame childhood asthma?
- Could everyday supplements shield your lungs?